Supernus Pharmaceuticals' stock soared 5.89% intraday on Tuesday, driven by the release of its fourth quarter and full-year 2025 financial results.

The company announced record financial performance, including Q4 adjusted revenue of $196.4 million and Q4 product sales of $158.1 million. Furthermore, Supernus provided an optimistic full-year outlook, projecting revenue between $840 million and $870 million and adjusted operating earnings in the range of $140 million to $170 million.

These strong results and positive guidance signal robust operational health and future growth potential, which fueled investor confidence and contributed to the stock's significant upward movement during the trading session.